Cellectar Biosciences to initiate fourth cohort of its Phase I clinical trial of CLR 131
Cellectar Biosciences announces the successful completion of Cohort 3 and initiation of Cohort 4 in the company's Phase I clinical study of CLR 131 in patients with relapsed and refractory multiple myeloma. Initiation of the fourth cohort occurs well ahead of the company's guidance. February 22, 2017